Two estimates $79.36M. Burning Rock Biotech announced that it expects the company’s full-year revenue growth for 2022 to be approximately 10% compared to that of 2021. This represents an upward revision compared with the company’s previous guidance on the full-year revenue growth of 5% as announced on November 15, 2022 in its financial results for the third quarter of 2022. The upward revision of revenue guidance was primarily driven by a better fourth quarter performance compared to the company’s estimation underlying its previous guidance back in November. The company currently expects its revenues for the fourth quarter of 2022 to drop single digit compared to the corresponding period in 2021, with revenues from its central-lab and in-hospital segments dropping double digit, due to severe Covid-related disruptions, while revenues from its pharma service segment achieving continued strong growth, growing at triple digit compared to the same period in 2021.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNR:
- Burning Rock provides an update on 2022 revenue guidance
- Burning Rock receives FDA Breakthrough Device Designation for OverC Test
- Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
- Burning Rock Biotech’s cancer detection test designated Breakthrough Device